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Percutaneous Coronary Interventions
Novel Insights From Pre-Treatment With
Glucagon-Like Peptide-1*Brigitta C. Brott, MDP atients undergoing high-risk percutaneouscoronary interventions (PCIs) are at increasedhazard of persistent hypotension and left ven-
tricular (LV) dysfunction as a result of myocardial
stunning. With the development of stunning, support
devices and inotropes are frequently called upon to
support the patient during and after procedures.
Myocardial stunning is deﬁned as the persistence of
LV dysfunction after ischemia, in the absence of irre-
versible damage (1). Its duration is variable, but it
often persists beyond 30 min, and repeated balloon
occlusions prompt additional LV dysfunction (2).
The mechanism of this persistent dysfunction is not
known; proposed mechanisms include generation of
oxygen-derived free radicals (3) or calcium overload
(4). To date, no medications have proven effective
in preventing this transient but potentially serious
deterioration in function.
The discovery that glucagon-like peptide-1 (GLP-1)
provides myocardial protection has generated sig-
niﬁcant scientiﬁc interest. GLP-1 is a 30 amino acid
peptide produced in the intestinal epithelium in
response to food intake (5). It is rapidly metabolized
by dipeptidyl peptidase-IV (DPP-4) to its primary
metabolite GLP-1(9-36), and the half-life of GLP-1 in
plasma is 2 to 3 min (6). The primary action of GLP-1 is
to stimulate insulin secretion and inhibit glucagon
secretion, and it appears to regulate appetite and food*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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receptor has been identiﬁed in the brain, peripheral
nervous system, intestinal tract, lung, kidney, and
heart (7). Two widely used classes of type II diabetes
therapies are degradation-resistant GLP-1 agonists
and DPP-4 inhibitors (8).
Animal and human studies suggest cardioprotective
effects of GLP-1 infusion and with GLP-1 analogue and
DPP-4 inhibitor administration. Proposed cardiovas-
cular effects include protection from ischemia reper-
fusion injury, improved LV function in dilated
cardiomyopathy, myocardial arterial vasodilation,
improved glucose metabolism, reduced blood pres-
sure, reduction in atherosclerotic lesions, and anti-
inﬂammatory effects (9,10). Importantly, the GLP-1
receptor appears to play a direct role in enhanced
cardiomyocyte survival in ischemia reperfusion injury
via the reperfusion injury survival kinase pathway (9).
Myocardial metabolism is a complex process and
varies depending on level of stress and availability
of the substrates glucose and free fatty acids (FFA)
(11). During stress, the myocardium shifts toward
glucose metabolism (12). The mechanisms by which
GLP-1, its degradation-resistant analogues, and DPP-4
inhibitors provide cardioprotection are not com-
pletely understood, although at least some of this
effect is thought to be via the GLP-1 receptor associ-
ated with increased myocardial glucose uptake (12).
Recent data in a mouse model suggests 2 different
GLP-1 dependent pathways of myocardial protection
(13). A GLP-1 receptor-dependent mechanism provides
an inotropic effect, increased glucose uptake, and
ischemic pre-conditioning. There appears to be a GLP-1
receptor-independent effect as well, which may in-
volve ischemic pre-conditioning and vasodilation.
The primary metabolite of GLP-1, GLP-1(9-36), was
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303previously thought to be inactive. However, more
recent evidence points to an additional cardiac
protective effect (9), including vasodilation through
a nitric oxide–dependent mechanism and car-
dioprotection from ischemia reperfusion injury
(9,13). How GLP-1(9-36) exerts its effects is not clear,
because a speciﬁc receptor for GLP-1(9-36) has not
yet been identiﬁed.
Clinical studies have demonstrated cardio-
protective effects with GLP-1 in a number of settings.
There is evidence for greater myocardial salvage
in the setting of ST-segment elevation myocardial
infarction (14,15). DPP-4 inhibition or GLP-1 infusion
improves LV function during dobutamine stress
echocardiography in patients with coronary artery
disease (16–18). In the setting of PCI, GLP-1 infusion
started after balloon occlusion provides improved LV
function and mitigates myocardial stunning (19).
Unanswered questions in the published studies
include: what are the settings in which GLP-1
administration is cardioprotective? Are the myocar-
dial effects mediated via the GLP-1 receptor and
glucose metabolism, or are there other pathways? In
the setting of myocardial ischemia and cardiac stun-
ning during PCI, is GLP-1 protective given in advance
or does it work via ischemic pre-conditioning/
antiapoptotic mechanisms and, therefore, only after
the initiation of ischemia?SEE PAGE 292In this issue of JACC: Cardiovascular Interventions,
McCormick et al. (20) set up an elegant clinical trial to
assess whether GLP-1 administration prior to balloon
occlusion mitigates stunning at 30 min. The in-
vestigators measured pressure volume loops in pa-
tients with LAD lesions and normal LV function.
Twenty patients were randomized to control versus
GLP-1 infusion initiated prior to balloon occlusion.
Those who received saline control developed a
decrease in LV function during ischemia that per-
sisted at 30 min. However, in those who receivedGLP-1 infusion, there was no decrease in LV function
at either time point. Pressure-volume loops revealed
reduced LV systolic function and impaired LV relax-
ation (Tau) with control infusion during balloon oc-
clusion, which largely persisted at 30 min, consistent
with stunning. With GLP-1 infusion, all LV function
parameters were not impaired and remained at
baseline, indicating a prevention of stunning. Ad-
ministration of GLP-1 led to anticipated changes in
systemic metabolic parameters. However, the in-
vestigators also obtained blood samples from the
coronary arteries and the coronary sinus to look at
glucose and FFA extraction by the heart. Surprisingly,
there was no difference in the amount of glucose or
FFA extracted by the heart after GLP-1 or control
administration, indicating that the cardioprotective
effect was independent of glucose uptake by the
heart.
These ﬁndings demonstrate that there may be an
additional myocardial metabolic pathway beyond
glucose metabolism by which LV function can be
protected from stunning in the setting of PCI.
Although this cardiac protection could be the result of
protection from ischemia reperfusion injury, this is
unlikely because this injury response is not initiated
until after balloon occlusion. This is a small study of
20 patients, but it provides important clues to the
existence of an alternative metabolic pathway for
GLP-1 effects. This could eventually lead to the
development of new therapies for the prevention of
myocardial stunning. What is not known from this
study is whether this protection is a direct effect of
GLP-1 or its metabolite GLP-1(9-36), or if degradation-
resistant GLP-1 receptor agonists or DPP-4 inhibitors
would have a similar effect.
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